Paraptosis and NF-κB activation are associated with protopanaxadiol-induced cancer chemoprevention

BMC Complementary and Alternative Medicine

Volumn 13, Issue , 2013, Pages

  Wang, Chong Zhi ^a,b   Li, Binghui ^c   Wen, Xiao Dong ^a,b   Zhang, Zhiyu ^a,b   Yu, Chunhao ^a,b   Calway, Tyler D ^a,b   He, Tong Chuan ^b   Du, Wei ^c   Yuan, Chun Su ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

Antioxidant; Cancer chemoprevention; Cytoplasmic vacuoles; Ginseng; Mitochondrial swelling; Paraptosis; PPD; Protopanaxadiol

Indexed keywords

CYCLOHEXIMIDE; FLUOROURACIL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTOPANAXADIOL; REACTIVE OXYGEN METABOLITE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL ASSAY; CELL DEATH; CELL STRAIN; CELL STRUCTURE; CELL VACUOLE; CHEMICAL STRUCTURE; COLORECTAL CANCER; CONTROLLED STUDY; CYTOPLASM; ENZYME ACTIVATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MITOCHONDRION; PARAPTOSIS; SIGNAL TRANSDUCTION; ULTRAVIOLET SPECTROPHOTOMETRY; ULTRAVIOLET VISIBLE SPECTROPHOTOMETRY;

ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL DEATH; CHEMOPREVENTION; COLORECTAL NEOPLASMS; HCT116 CELLS; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; MITOCHONDRIA; NF-KAPPA B; PANAX; PHYTOTHERAPY; PLANT EXTRACTS; PYRIDINES; REACTIVE OXYGEN SPECIES; SAPOGENINS; SIGNAL TRANSDUCTION; VACUOLES;

EID: 84871722760     PISSN: None     EISSN: 14726882     Source Type: Journal    
DOI: 10.1186/1472-6882-13-2     Document Type: Article

References (32)

1. Wood CG. Multimodal approaches in the management of locally advanced and metastatic renal cell carcinoma: combining surgery and systemic therapies to improve patient outcome. Clin Cancer Res 2007, 13(2 Pt 2):697s-702s.
2. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, Gutberlet K, Kettner E, Schmalenberg H, Weigang-Koehler K, Bechstein WO, Niedergethmann M, Schmidt-Wolf I, Roll L, Doerken B, Riess H. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007, 297(3):267-277. 10.1001/jama.297.3.267, 17227978.
3. Biagi JJ, Raphael MJ, Mackillop WJ, Kong W, King WD, Booth CM. Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis. JAMA 2011, 305(22):2335-2342. 10.1001/jama.2011.749, 21642686.
4. Wang CZ, Calway T, Yuan CS. Herbal medicines as adjuvants for cancer therapeutics. Am J Chin Med 2012, 40(4):657-669. 10.1142/S0192415X12500498, 3415888, 22809022.
5. Bougnoux P, Hajjaji N, Maheo K, Couet C, Chevalier S. Fatty acids and breast cancer: sensitization to treatments and prevention of metastatic re-growth. Prog Lipid Res 2010, 49(1):76-86. 10.1016/j.plipres.2009.08.003, 19715726.
6. Lee KH. Discovery and development of natural product-derived chemotherapeutic agents based on a medicinal chemistry approach. J Nat Prod 2010, 73(3):500-516. 10.1021/np900821e, 2893734, 20187635.
7. Qi LW, Wang CZ, Yuan CS. American ginseng: potential structure-function relationship in cancer chemoprevention. Biochem Pharmacol 2010, 80(7):947-954. 10.1016/j.bcp.2010.06.023, 20599804.
8. Xu Z, Chen X, Zhong Z, Chen L, Wang Y. Ganoderma lucidum polysaccharides: immunomodulation and potential anti-tumor activities. Am J Chin Med 2011, 39(1):15-27. 10.1142/S0192415X11008610, 21213395.
9. Yun TK. Panax ginseng-a non-organ-specific cancer preventive?. Lancet Oncol 2001, 2(1):49-55. 10.1016/S1470-2045(00)00196-0, 11905620.
10. Yun TK, Zheng S, Choi SY, Cai SR, Lee YS, Liu XY, Cho KJ, Park KY. Non-organ-specific preventive effect of long-term administration of Korean red ginseng extract on incidence of human cancers. J Med Food 2010, 13(3):489-494. 10.1089/jmf.2009.1275, 20521975.
11. Li XL, Wang CZ, Mehendale SR, Sun S, Wang Q, Yuan CS. Panaxadiol, a purified ginseng component, enhances the anti-cancer effects of 5-fluorouracil in human colorectal cancer cells. Cancer Chemother Pharmacol 2009, 64(6):1097-1104. 10.1007/s00280-009-0966-0, 19277659.
12. Fishbein AB, Wang CZ, Li XL, Mehendale SR, Sun S, Aung HH, Yuan CS. Asian ginseng enhances the anti-proliferative effect of 5-fluorouracil on human colorectal cancer: comparison between white and red ginseng. Arch Pharm Res 2009, 32(4):505-513. 10.1007/s12272-009-1405-9, 19407967.
13. Hwang JW, Oh JH, Yoo HS, Lee YW, Cho CK, Kwon KR, Yoon JH, Park J, Her S, Lee ZW, Jang IS, Choi JS. Mountain ginseng extract exhibits anti-lung cancer activity by inhibiting the nuclear translocation of NF-kappaB. Am J Chin Med 2012, 40(1):187-202. 10.1142/S0192415X12500152, 22298458.
14. Wang CZ, Aung HH, Ni M, Wu JA, Tong R, Wicks S, He TC, Yuan CS. Red American ginseng: ginsenoside constituents and antiproliferative activities of heat-processed Panax quinquefolius roots. Planta Med 2007, 73(7):669-674. 10.1055/s-2007-981524, 2657361, 17538869.
15. Sun S, Qi LW, Du GJ, Mehendale SR, Wang CZ, Yuan CS. Red notoginseng: higher ginsenoside content and stronger anticancer potential than Asian and American ginseng. Food Chem 2011, 125(4):1299-1305. 10.1016/j.foodchem.2010.10.049, 3041968, 21344064.
16. Li B, Zhao J, Wang CZ, Searle J, He TC, Yuan CS, Du W. Ginsenoside Rh2 induces apoptosis and paraptosis-like cell death in colorectal cancer cells through activation of p53. Cancer Lett 2011, 301(2):185-192. 10.1016/j.canlet.2010.11.015, 3022099, 21194832.
17. Wang CZ, Zhang B, Song WX, Wang A, Ni M, Luo X, Aung HH, Xie JT, Tong R, He TC, Yuan CS. Steamed American ginseng berry: ginsenoside analyses and anticancer activities. J Agric Food Chem 2006, 54(26):9936-9942. 10.1021/jf062467k, 17177524.
18. Du GJ, Dai Q, Williams S, Wang CZ, Yuan CS. Synthesis of protopanaxadiol derivatives and evaluation of their anticancer activities. Anticancer Drugs 2011, 22(1):35-45. 10.1097/CAD.0b013e32833fde29, 2992804, 20926945.
19. Chen TS, Wang XP, Sun L, Wang LX, Xing D, Mok M. Taxol induces caspase-independent cytoplasmic vacuolization and cell death through endoplasmic reticulum (ER) swelling in ASTC-a-1 cells. Cancer Lett 2008, 270(1):164-172. 10.1016/j.canlet.2008.05.008, 18547714.
20. Greenlee H, Gammon MD, Abrahamson PE, Gaudet MM, Terry MB, Hershman DL, Desai M, Teitelbaum SL, Neugut AI, Jacobson JS. Prevalence and predictors of antioxidant supplement use during breast cancer treatment: the Long Island Breast Cancer Study Project. Cancer 2009, 115(14):3271-3282. 10.1002/cncr.24378, 2763503, 19507173.
21. Myung SK, Kim Y, Ju W, Choi HJ, Bae WK. Effects of antioxidant supplements on cancer prevention: meta-analysis of randomized controlled trials. Ann Oncol 2010, 21(1):166-179. 10.1093/annonc/mdp286, 19622597.
22. Fernandez-Gomez FJ, Galindo MF, Gomez-Lazaro M, Gonzalez-Garcia C, Cena V, Aguirre N, Jordan J. Involvement of mitochondrial potential and calcium buffering capacity in minocycline cytoprotective actions. Neuroscience 2005, 133(4):959-967. 10.1016/j.neuroscience.2005.03.019, 15964487.
23. Qi LW, Wang CZ, Yuan CS. Ginsenosides from American ginseng: chemical and pharmacological diversity. Phytochemistry 2011, 72(8):689-699. 10.1016/j.phytochem.2011.02.012, 3103855, 21396670.
24. Qi LW, Wang CZ, Yuan CS. Isolation and analysis of ginseng: advances and challenges. Nat Prod Rep 2011, 28(3):467-495. 10.1039/c0np00057d, 3056508, 21258738.
25. Wang CZ, Kim KE, Du GJ, Qi LW, Wen XD, Li P, Bauer BA, Bissonnette MB, Musch MW, Chang EB, Yuan CS. Ultra-performance liquid chromatography and time-of-flight mass spectrometry analysis of ginsenoside metabolites in human plasma. Am J Chin Med 2011, 39(6):1161-1171. 10.1142/S0192415X11009470, 3246195, 22083988.
26. Wang HY, Qi LW, Wang CZ, Li P. Bioactivity enhancement of herbal supplements by intestinal microbiota focusing on ginsenosides. Am J Chin Med 2011, 39(6):1103-1115. 10.1142/S0192415X11009433, 3349338, 22083984.
27. Din FV, Dunlop MG, Stark LA. Evidence for colorectal cancer cell specificity of aspirin effects on NF kappa B signalling and apoptosis. Br J Cancer 2004, 91(2):381-388. 2409803, 15188000.
28. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003, 3(5):330-338. 10.1038/nrc1074, 12724731.
29. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000, 355(9209):1041-1047. 10.1016/S0140-6736(00)02034-1, 10744089.
30. Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y, Coudert B, Bertheaut-Cvitkovic F, Larregain-Fournier D, Le Rol A, Walter S, Adam R, Misset JL, Levi F. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000, 18(1):136-147.
31. Choudhary B, Hanski ML, Zeitz M, Hanski C. Proliferation rate but not mismatch repair affects the long-term response of colon carcinoma cells to 5FU treatment. Cancer Lett 2012, 320(1):56-64. 10.1016/j.canlet.2012.01.025, 22266192.
32. Du GJ, Wang CZ, Qi LW, Zhang ZY, Calway T, He TC, Du W, Yuan CS. The synergistic apoptotic interaction of panaxadiol and epigallocatechin gallate in human colorectal cancer cells. Phytother Res 2012, 26. In press.